Skip to main content


To view more alumni events, click here.

Cryptography Roundtable Discussion
Sep 18 @ 10:00 am – 11:00 am

Recent news reports stated that the National Security Agency has pursued new methods that have allowed the agency to monitor telephone and online communication, encrypted information that was thought to be virtually immune to eavesdropping. What steps can and should computer scientists take in response to this privacy threat? How will the recent revelations affect the future of cryptography—the field of encoding and decoding electronic communication and transmissions for the purposes of privacy, reliability and efficiency?

To address these questions, the Johns Hopkins University Information Security Institute will host an hour-long roundtable discussion, moderated by Anton Dahbura, interim executive director of the Information Security Institute, and Avi Rubin, the institute’s technical director. Other participants will include Johns Hopkins cyber-security experts Matthew Green, Stephen Checkoway and Giuseppe Ateniese.

The event will be streamed live at, and also will be posted online following the event.


NOTE: Seating at this public event will be limited. Members of the media who plan to cover the discussion are asked to RSVP to Phil Sneiderman,

ICM Distinguished Seminar Series presents “Change Point Estimation of Brain Shape Data in Relation with Alzheimer’s Disease”
Nov 1 @ 11:00 am – 12:00 pm
ICM Distinguished Seminar Series presents "Change Point Estimation of Brain Shape Data in Relation with Alzheimer's Disease" @ Clark Hall 110, VTC to Traylor 709

Laurent Younes, professor and chair of the Department of Applied Mathematics and Statistics at Johns Hopkins University, will present “Change Point Estimation of Brain Shape Data in Relation with Alzheimer’s Disease.”

Abstract: The manifestation of an event, such as the onset of a disease, is not always immediate and often requires some time for its repercussions to become observable. Slowly progressing diseases, and in particular neuro-degenerative disorders such as Alzheimer’s disease (AD), fall into this category. The manifestation of such diseases is related to the onset of cognitive or functional impairment and, at the time when this occurs, the disease may have already had been affecting the brain anatomically and functionally for a considerable time. We consider a statistical two-phase regression model in which the change point of a disease biomarker is measured relative to another point in time, such as the manifestation of the disease, which is subject to right-censoring (i.e., possibly unobserved over the entire course of the study). We develop point estimation methods for this model, based on maximum likelihood, and bootstrap validation methods. The effectiveness of our approach is illustrated by numerical simulations, and by the estimation of a change point for atrophy in the context of Alzheimer’s disease, wherein it is related to the cognitive manifestation of the disease. This work is a collaboration with Marilyn Albert, Xiaoying Tang and Michael Miller, and was partially supported by the NIH.

For those who cannot make it to the Homewood campus, the seminar will be video-conferenced to Traylor 709 on the School of Medicine campus.

For those who attend at Homewood, lunch will be provided at noon.

Canceled – Robert Nerem presents “Regenerative Medicine: The Hype, the Hope, and the Future”
Apr 14 @ 3:30 pm – 4:30 pm
Canceled - Robert Nerem presents "Regenerative Medicine: The Hype, the Hope, and the Future" @ 26 Mudd Hall

This event has been canceled.

Robert M. Nerem (Georgia Institute of Technology) presents “Regenerative Medicine: The Hype, the Hope, and the Future” as part of a special seminar hosted by the Department of Biomedical Engineering, the Institute for NanoBioTechnology, and the Translational Tissue Engineering Center.

Abstract: Although the underlying concepts of tissue engineering and regenerative medicine go back more than 75 years, the term tissue engineering actually was only “coined” in the 1980s. This was followed by the 1990s being the “go-go” years with stem cells emerging as a technology, an industry developing, and the term regenerative medicine beginning to be used. There also was a lot of hype, and following the turn of the century the field entered what might be called the “sobering” years, with private sector activity falling significantly even though the science continued to advance. The last decade, however, has all the marks of being “back to the future.” Advances in cell-based therapies have been fueled by advances in stem cell science and technology and the discovery of what is required to reprogram somatic cells into stem cells, known as induced pluripotent stem (iPS) cells. For cellular therapies, a key question is what is the mechanism of action? For a specific therapy, is the mechanism one of cell replacement or is it a paracrine effect? If the latter, is it possible that one could introduce the appropriate biological signals without the use of cells? In this case the discussion shifts from “my cell is better than your cell” to “my biological signals are better than yours.” Whatever the case, one of the “holy grails” is the neurodegenerative diseases/disorders and the repair/regeneration of the central nervous system. Instead of the mixture of hype and hope in the past, and with an aging population providing the threat of a “tsunami” of neural disorders, regenerative medicine offers the real possibility of cures to these diseases/disorders in the future.

Back to top